SG11201810429UA - Anti-cd19 antibody formulations - Google Patents
Anti-cd19 antibody formulationsInfo
- Publication number
- SG11201810429UA SG11201810429UA SG11201810429UA SG11201810429UA SG11201810429UA SG 11201810429U A SG11201810429U A SG 11201810429UA SG 11201810429U A SG11201810429U A SG 11201810429UA SG 11201810429U A SG11201810429U A SG 11201810429UA SG 11201810429U A SG11201810429U A SG 11201810429UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- planegg
- pct
- ingelheim
- semmelweisstr
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 0 1111111111111111111111111111 1111111111111111111 01011111 0111 0111111101111 011111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/002031 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2017/065819 (22) International Filing Date: 27 June 2017 (27.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16176322.2 27 June 2016 (27.06.2016) EP (71) Applicant: MORPHOSYS AG [DE/DE]; Semmelweis- strasse 7, 82152 Martinsried/Planegg (DE). (72) Inventors: GARIDEL, Patrick; Boehringer Ingelheim GmbH, Binger Str. 173, 55216 Ingelheim am Rhein (DE). LANGER, Andreas; Boehringer Ingelheim GmbH, Binger _ Str. 173, 55216 Ingelheim am Rhein (DE). HESSLING, Martin; Dinglingerstr. 19/1, 88400 Biberach an der RiB (DE). WEINFURTNER, Daniel; MorphoSys AG, Sem- - melweisstr. 7, 82152 Planegg (DE). BROCKS, Bodo; Mor- phoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). = = Agent: SPIELER, Stephan; Semmelweisstr. 7, 82152 (74) — Planegg (DE). = = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, _ = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — 1-1 KM, ML, MR, NE, SN, TD, TG). 1-1 Published: M — with international search report (Art. 21(3)) 0 — ei with sequence listing part of description (Rule 5.2(a)) © © -.... 00 1-1 (54) Title: ANTI-CD19 ANTIBODY FORMULATIONS 0 ei (57) : The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176322 | 2016-06-27 | ||
| PCT/EP2017/065819 WO2018002031A1 (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810429UA true SG11201810429UA (en) | 2018-12-28 |
Family
ID=56368805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810429UA SG11201810429UA (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
| SG10201912369QA SG10201912369QA (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912369QA SG10201912369QA (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11352423B2 (en) |
| EP (2) | EP3475303B1 (en) |
| JP (3) | JP2019524671A (en) |
| KR (2) | KR102533875B1 (en) |
| CN (2) | CN109415440B (en) |
| AU (2) | AU2017289085B2 (en) |
| CA (1) | CA3029137A1 (en) |
| CY (1) | CY1124521T1 (en) |
| DK (1) | DK3475303T3 (en) |
| ES (1) | ES2874640T3 (en) |
| HR (1) | HRP20210945T1 (en) |
| HU (1) | HUE054296T2 (en) |
| IL (1) | IL263764B2 (en) |
| LT (1) | LT3475303T (en) |
| MA (1) | MA45450B1 (en) |
| MD (1) | MD3475303T2 (en) |
| MX (1) | MX2018016362A (en) |
| PL (1) | PL3475303T3 (en) |
| PT (1) | PT3475303T (en) |
| RS (1) | RS62035B1 (en) |
| RU (1) | RU2748024C2 (en) |
| SG (2) | SG11201810429UA (en) |
| SI (1) | SI3475303T1 (en) |
| SM (1) | SMT202100317T1 (en) |
| WO (1) | WO2018002031A1 (en) |
| ZA (1) | ZA201900483B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (en) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Combinations and use thereof |
| KR102735988B1 (en) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | therapeutic antibody preparations |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| WO2021084063A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| AU2021298106A1 (en) | 2020-06-22 | 2023-01-19 | Gilead Sciences, Inc. | Anti-tumor combination therapy comprising anti-CD19 antibody and polypeptides blocking the SIRPalpha-CD47 innate immune checkpoint |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Duplexbodies |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| IL312060A (en) | 2021-11-03 | 2024-06-01 | Affimed Gmbh | Bispecific CD16A binders |
| IL316747A (en) * | 2022-05-03 | 2025-01-01 | Xencor Inc | Methods for treating lymphoma |
| WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| WO2024180511A1 (en) * | 2023-03-02 | 2024-09-06 | Novetide Ltd. | Process for preparation of glp-1 peptides having controlled particle size |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| MX2007015944A (en) | 2005-06-20 | 2008-03-07 | Medarex Inc | Cd19 antibodies and their uses. |
| BRPI0620795A2 (en) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschronkter Haftung | anti-cd19 antibodies reduced immunogenicity |
| WO2008022152A2 (en) * | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
| RU2495882C2 (en) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Humanised cd19 antibodies and using them for treating transplantation-related oncological and autoimmune disease |
| EP2708557A1 (en) | 2007-05-30 | 2014-03-19 | Xencor, Inc. | Method and compositions for inhibiting CD32B expressing cells |
| WO2009041643A1 (en) * | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| PL2211904T3 (en) | 2007-10-19 | 2017-04-28 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| SG173654A1 (en) | 2009-02-23 | 2011-09-29 | Glenmark Pharmaceuticals Sa | Humanized antibodies that bind to cd19 and their uses |
| RU2011140486A (en) * | 2009-03-06 | 2013-04-20 | МЕДИММЬЮН, ЭлЭлСи | COMPOSITIONS CONTAINING HUMANIZED ANTIBODIES TO CD19 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| NZ711567A (en) | 2013-03-13 | 2020-04-24 | Genentech Inc | Antibody formulations |
| BR112015022484A2 (en) | 2013-03-13 | 2017-07-18 | Genentech Inc | reduced oxidation formulations |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| DK3049441T3 (en) | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1 antibody formulations |
| EP4420729A3 (en) * | 2013-11-21 | 2024-10-30 | Genmab A/S | Antibody-drug conjugate formulation |
| CA2942150A1 (en) * | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
-
2017
- 2017-06-27 SG SG11201810429UA patent/SG11201810429UA/en unknown
- 2017-06-27 HU HUE17735440A patent/HUE054296T2/en unknown
- 2017-06-27 SI SI201730801T patent/SI3475303T1/en unknown
- 2017-06-27 CN CN201780039737.6A patent/CN109415440B/en active Active
- 2017-06-27 KR KR1020197002043A patent/KR102533875B1/en active IP Right Grant
- 2017-06-27 PL PL17735440T patent/PL3475303T3/en unknown
- 2017-06-27 MX MX2018016362A patent/MX2018016362A/en unknown
- 2017-06-27 DK DK17735440.4T patent/DK3475303T3/en active
- 2017-06-27 RS RS20210748A patent/RS62035B1/en unknown
- 2017-06-27 CN CN202211458395.0A patent/CN115998859A/en active Pending
- 2017-06-27 WO PCT/EP2017/065819 patent/WO2018002031A1/en unknown
- 2017-06-27 EP EP17735440.4A patent/EP3475303B1/en active Active
- 2017-06-27 IL IL263764A patent/IL263764B2/en unknown
- 2017-06-27 KR KR1020237016157A patent/KR20230074823A/en not_active Application Discontinuation
- 2017-06-27 MA MA45450A patent/MA45450B1/en unknown
- 2017-06-27 AU AU2017289085A patent/AU2017289085B2/en active Active
- 2017-06-27 CA CA3029137A patent/CA3029137A1/en active Pending
- 2017-06-27 RU RU2019100221A patent/RU2748024C2/en active
- 2017-06-27 MD MDE20190533T patent/MD3475303T2/en unknown
- 2017-06-27 JP JP2018567742A patent/JP2019524671A/en active Pending
- 2017-06-27 SM SM20210317T patent/SMT202100317T1/en unknown
- 2017-06-27 SG SG10201912369QA patent/SG10201912369QA/en unknown
- 2017-06-27 LT LTEP17735440.4T patent/LT3475303T/en unknown
- 2017-06-27 US US16/310,555 patent/US11352423B2/en active Active
- 2017-06-27 ES ES17735440T patent/ES2874640T3/en active Active
- 2017-06-27 EP EP21167818.0A patent/EP3909985A1/en active Pending
- 2017-06-27 PT PT177354404T patent/PT3475303T/en unknown
-
2019
- 2019-01-23 ZA ZA2019/00483A patent/ZA201900483B/en unknown
-
2021
- 2021-06-14 CY CY20211100532T patent/CY1124521T1/en unknown
- 2021-06-14 HR HRP20210945TT patent/HRP20210945T1/en unknown
-
2022
- 2022-03-22 US US17/700,809 patent/US20220213190A1/en active Pending
- 2022-05-18 JP JP2022081779A patent/JP7603201B2/en active Active
-
2024
- 2024-05-23 JP JP2024083988A patent/JP2024109816A/en active Pending
- 2024-07-24 AU AU2024205042A patent/AU2024205042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation |